Importance Epilepsy affects approximately 65 million people worldwide. Persistent seizures
are associated with a 20% to 40% risk of bodily injuries (eg, fractures, burns, concussions) …

Abstract Background Antiseizure drugs (ASDs) are the primary therapy for epilepsy, with
more than 20 drugs introduced into clinical practice to date. These drugs are typically …

Objectives To compare the time to treatment failure, remission and first seizure of 12 AEDs
(carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine …

The purpose of this report was to update the 2006 International League Against Epilepsy
(ILAE) report and identify the level of evidence for long‐term efficacy or effectiveness for …

Background Carbamazepine is widely accepted as a drug of first choice for patients with
partial onset seizures. Several newer drugs possess efficacy against these seizure types but …

Purpose: To assess which antiepileptic medications (AEDs) have the best evidence for long‐
term efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or …

Thirty-five years since its introduction into clinical use, valproate (valproic acid) has become
the most widely prescribed antiepileptic drug (AED) worldwide. Its pharmacological effects …

Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has
become established worldwide as one of the most widely used AEDs in the treatment of both …

Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven
new antiepileptic drugs (AEDs)(gabapentin, lamotrigine, topiramate, tiagabine …

Objective: We report the results of a prospective study of the efficacy and tolerability of
levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison …